|
Rifaximin
API |
|
|
|
Haorui supplies high quality Rifaximin API produced by our
GMP facility that has been successfully inspected by the
FDA.
We offer
competitive prices and support our products with reliable technical and
regulatory services. Rifaximin API is available from R&D to
commercial quantities. Please contact us for more details. |
| |
|
The following
information is provided for general information purposes
ONLY. |
|
|
|
Patented products available for
research and development use as permitted under CFR
35 section 271(e)(1).
|
|
Generic
Name: Rifaximin |
|
Treatment
for: Travelers' Diarrhea |
|
|
|
The
U.S. Food and Drug Administration (FDA) has granted
marketing approval for rifaximin tablets
200 mg for the treatment of travelers' diarrhea
caused by noninvasive strains of E. coli in patients
12 years of age and older.
|
|
|
|
Rifaximine
is a derivative of Rifamycin, which acts by
inhibiting bacterial ribonucleic acid (RNA)
synthesis. Rifaximin is a nonsystemic (less than 0.4% of the
drug absorbed into the bloodstream),
gastrointestinal-selective, oral antibiotic.
Rifaximin tablets are indicated for the treatment
of patients (12 years of age and older) with
travelers' diarrhea caused by noninvasive strains of
Escherichia coli.
|
|
|
|
Rifaximin should not be used in patients with
diarrhea complicated by fever or blood in the stool
or diarrhea due to pathogens other than Escherichia
coli. Rifaximin should be discontinued if
diarrhea symptoms get worse or persist more than
24-48 hours and alternative antibiotic therapy
should be considered.
|
|
|
|
In
clinical trials, Rifaximin was generally
well tolerated. The most common side effects (vs.
placebo) were flatulence 11.3% (vs. 19.7%), headache
9.7% (vs. 9.2%), abdominal pain 7.2% (vs. 10.1 %)
and rectal tenesmus 7.2% (vs. 8.8%). For full
prescribing information on Rifaximin
tablets and other Salix products, please visit www.salix.com.
|
|
|
|
FDA
has approved rifaximin, an oral,
gastrointestinal-selective antibiotic indicated for
treatment of patients aged 12 years or older with
travelers’ diarrhea caused by noninvasive strains
of Escherichia coli. Currently, rifaximin is approved in 17 countries worldwide.
|
|
|
|
In
clinical trials, rifaximin shortened the duration of
diarrhea for the most common cause of this disease,
noninvasive strains of E. coli. Unlike
systemically absorbed anti-infective agents,
rifaximin’s beneficial effect was achieved with
minimal systemic absorption (about 0.4%), thus
reducing the potential for development of systemic
antimicrobial resistance and other systemic concerns
such as drug–drug interactions.
|
|
|
|
Additionally,
rifaximin’s tolerability profile was comparable
with that observed with placebo. The most common
adverse effects were flatulence in 11.3% of patients
taking rifaximin (19.7% of placebo recipients had
this adverse effect); headache, 9.7% (9.2%);
abdominal pain, 7.2% (10.1%); and rectal tenesmus,
7.2% (8.8%). The drug should be discontinued and
alternative antibiotic therapy considered if
diarrhea symptoms get worse or persist more than
24–48 hours.
|
|
|
|
Disclaimer:
|
|
Information on
this page is provided for general information
purposes. You should not make a clinical treatment
decision based on information contained in this page
without consulting other references including the
package insert of the drug, textbooks and where
relevant, expert opinion. We cannot be held
responsible for any errors you make in administering
drugs mentioned on this page, nor for use of any
erroneous information contained on this page.
|
|
|
